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AbsTrACT
Objective a gluten-free diet is the only treatment 
option of coeliac disease, but recently an increasing 
number of trials have begun to explore alternative 
treatment strategies. We aimed to review the literature 
on coeliac disease therapeutic trials and issue 
recommendations for outcome measures.
Design Based on a literature review of 10 062 
references, we (17 researchers and 2 patient 
representatives from 10 countries) reviewed the use 
and suitability of both clinical and non-clinical outcome 
measures. We then made expert-based recommendations 
for use of these outcomes in coeliac disease trials and 
identified areas where research is needed.
results We comment on the use of histology, serology, 
clinical outcome assessment (including patient-reported 
outcomes), quality of life and immunological tools 
including gluten immunogenic peptides for trials in 
coeliac disease.
Conclusion careful evaluation and reporting of 
outcome measures will increase transparency and 
comparability of coeliac disease therapeutic trials, and 
will benefit patients, healthcare and the pharmaceutical 
industry.
InTrODuCTIOn
Coeliac disease (CD) is an immune-mediated disease 
triggered by gluten exposure.1 Although character-
ised by small intestinal inflammation, consequences 
are widespread and linked to diverse manifestations 
that include osteoporosis,2 lymphoma,3 4 pneu-
monia5 and increased mortality.6 Symptoms vary, 
with some patients having diarrhoea and malab-
sorption (often termed ‘classical CD’), others 
suffering from constipation, fatigue and depression 
(non-classical CD) and some are asymptomatic 
(subclinical CD).7 The global prevalence of CD is 
about 1%–2%,8 9 but seems to be increasing.10 11
Lifelong adherence to a gluten-free diet (GFD) 
is the only available treatment for CD.1 For several 
reasons, patients find the GFD to be exceedingly 
burdensome,12 that is, it is socially restrictive13 and 
more expensive than ordinary food.14–16 Patients 
differ in their ability to adapt psychologically to 
CD. Some people have little difficulty in adopting 
the GFD, whereas for others, living with CD is a 
daily struggle.13 In addition to the burden of treat-
ment, patients with CD frequently have ongoing 
symptoms and mucosal healing is slow and often 
incomplete. For these reasons, there is a need for 
alternative treatments of CD, as suggested by the 
intensive research efforts undertaken in different 
laboratories.17 Potential targets for treatment 
include glutenases, modified or pretreated gluten, 
gluten sequestrants, neutralising antibodies, 
inhibitors of intestinal permeability, lymphocyte 
blockers, including anti-interleukin-15, tissue 
transglutaminase (TG2) inhibitors, immune toler-
ance induction, exposure to hookworms and 
significance of this study
What is already known about this subject?
 ► A gluten-free diet is the only treatment option 
of coeliac disease, but recently an increasing 
number of trials have begun to explore 
alternative treatment strategies.
 ► A large number of trials of non-dietary 
treatments for coeliac disease are ongoing or 
under way.
 ► There is no consensus on outcome measures in 
coeliac disease trials.
What are the new findings?
 ► After an extensive literature review, 17 
researchers and 2 patient representatives from 
10 countries reviewed the use and suitability 
of histology, serology, clinical outcome 
assessment (including patient-reported 
outcomes), quality of life and immunological 
tools that comprised gluten immunogenic 
peptides for trials in coeliac disease.
 ► In this paper, we make expert-based 
recommendations for use of these outcomes in 
coeliac disease therapeutic trials.
How might it impact on clinical practice in the 
foreseeable future?
 ► Following the outlined recommendations of 
this paper, will increase transparency and 
comparability of coeliac disease therapeutic 
trials with benefit to patients, healthcare and 
the pharmaceutical industry.
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DQ2-blocking peptide analogues.17 18 Several of these drugs 
are now being tested in phase I or phase II trials, and a recent 
study found that novel therapies attract the interest of patients 
with CD more than any other disease-related topic.19
Of importance is that treatment effects are measured against 
robust standards. A recent systematic review20 identified six histo-
logical CD activity indices,21–26 five patient-reported outcomes 
(PROs)27–31 and four indices for endoscopic CD activity32–35 that 
have been used for coeliac trials.
In the present paper, we have explored clinical, serolog-
ical, histological and immunological outcome measures for 
performing clinical trials in CD, and importantly, have included 
the patient perspectives concerning recommendations for their 
use.
MeTHODs
Task force
Coauthors were invited by JFL and DAL with the aim to obtain 
a group with knowledge, experiences and interests that reflect 
the heterogeneity of outcome measures used in trials of CD. 
Most of the participating researchers were adult gastroenterol-
ogists (PHRG, CC, DSS, KKa, DS, JAM, JT, KEAL, DAL) but 
our group also included six paediatricians (JFL, NRR, KKu, 
MJM, AP, IRK-S), one pathologist (MMW), one basic scientist 
(AR-H) and two representatives of patient organisations (SS and 
KV). Members of this diverse collaboration originated from 10 
countries. Most of the coauthors participated in the CD meeting 
organised by MJM in Tampere, Finland on 24–25 November 
2016 (which provides the motivation for the subtitle of this 
paper).
Literature review
Coauthors were divided into seven teams of three to four indi-
viduals who jointly reviewed five domains: serology, histology, 
immunology, PROs and other outcome measures. The Karo-
linska Institutet library carried out literature searches for 
relevant papers up until 1 December 2016 (see online supple-
mentary appendix). This search yielded 10 062 references. After 
reviewing titles and abstracts for these 10 062 references (online 
supplementary appendix), there remained 941 publications that 
were considered potentially relevant for this review and subse-
quently read in detail.
In this paper, we issued a number of recommendations. 
Where appropriate these were graded according to the method 
suggested by the Oxford Centre or Evidence-based Medicine,36 
where grade A evidence represents the highest level of evidence 
and grade D the lower available evidence (generally based on 
the opinion of experts but with no preceding randomised trials, 
cohort or case-control studies). The appendix contains a detailed 
description of grade A–D. All recommendations were subject to a 
post hoc voting on a five-level scale (strongly disagree, disagree, 
not agree or disagree, agree and strongly agree).
Manuscript draft
JFL wrote the first draft of the paper. The text was then exten-
sively revised by the coauthors. JFL and DAL supervised these 
revisions, but all authors contributed and agreed on the conclu-
sions and the final wording of the paper.
This is a series of expert-based recommendations and did 
not meet the requirements of a formal systematic review (eg, 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement37). We aimed to highlight the state-of-
the-art of designing intervention trials in CD.
resuLTs
Histology
Clinicopathological correlation is key to the diagnosis of CD 
in adults and children. In adults, confirmation of the diag-
nosis by duodenal biopsy is the gold standard.7 38 39 In Europe, 
a ‘biopsy-sparing’ protocol (with defined limitations for use) 
has been adopted for symptomatic children defined by an anti-
TG2 titre ≥10 times the upper limit of normal, positive endo-
mysial antibody (EMA) on a second blood draw and positivity 
for human leucocyte antigen haplotypes HLA-DQ2 and/or 
HLA-DQ8.40 To evaluate effective treatment for CD, quantita-
tive histological assessment (morphometry) outperforms qualita-
tive histology (eg, the Marsh score) in a trial setting.20 In clinical 
trials, optimised biopsy protocols should be followed for assess-
ment of mucosal damage or healing.
Well-known classifications in histological assessment are 
described by Marsh and modified by Oberhuber7 38 and Corazza 
and Villanacci.41 Although grouped classifications are practical 
in clinical work, recent studies have shown imperfect reproduc-
ibility and reliability.26 42
Recently published recommendations for biopsy diagnosis of 
CD in adult patients for the number of biopsies and sites are 
available,38 39 with optimal laboratory processing alongside struc-
tured reports to include validated morphometric analysis.26 38
It is recommended to take at least five duodenal biopsies, one 
or two from the duodenal bulb (D1) and four from the second 
part of the duodenum (D2).38 39 These biopsies should be taken 
across circular folds to avoid a crushing artefact.43 Endoscopists 
should take one biopsy specimen per pass of the forceps in that 
a single-biopsy technique improves the yield of well-oriented 
duodenal biopsy specimens.44 Biopsies from D1 and D2 should 
be reviewed separately by a pathologist.45
When processed in the laboratory, biopsies should be oriented 
correctly and sectioned at three levels. In trial settings it is 
appropriate to always count intraepithelial lymphocytes (IELs) 
and state the number present/100 enterocytes (normal counts 
are ≤25/100 enterocytes).7 26 39 45 46 IELs can be counted in H&E 
stained sections; however, immunohistochemistry with CD3 is 
preferred by some pathologists.26 47 Frozen tissue specimens 
have been used to evaluate T-cell receptor gamma delta positive 
(γδ+) T cells,48 but new antibodies for use on paraffin-embedded 
specimens are now available.49 50 Identification of a high density 
of γδ+ T cells is relatively specific for CD and can be useful when 
histological diagnosis remains equivocal.48 49
Immunohistochemistry to show deposited immunoglobulin 
A targeting TG2 in the small bowel mucosa is accurate in the 
detection of CD if patients are on a gluten-containing diet.51 
These deposits have had 100% sensitivity52 and a mean speci-
ficity of 94%53 for CD. The deposits have been used in several 
gluten challenge studies to measure gluten reactivity.52 This tech-
nique requires the use of frozen tissue. The use of frozen tissue in 
clinical trials has shown variable results, which mirrored serum 
TG2 antibodies with increased deposits.54
Morphometry, in which continuous variables such as the 
villous height-to-crypt depth ratio and IEL density are measured 
separately, overcomes certain problems encountered when using 
grouped classifications.26 55 Of note, a threshold change of 0.4 
represents a measurable and likely clinically relevant differ-
ence between villous height:crypt depth ratio measurements. A 
villous height:crypt depth ratio of <2 is indicative of atrophy, 
active disease. Patients with treated CD have values above 3. 
Similarly, ≥30% change in T-cell IEL densities is considered clin-
ically significant.26
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Importantly, morphometry, which has produced excellent 
reproducibility and reliability,26 has a significant role in clinical 
trials in which reliable and accurate measurements are a require-
ment.56 Whichever classification is used, two blinded observers 
should read the histology to ensure reliability in clinical trials.26 
It should be noted that CD can be patchy and there is some intra-
subject and even intrabiopsy variability in villous architecture 
and lymphocyte numbers contributing to sampling error and 
difficulties in interpretation. Given this, and that only a small 
proportion of the proximal small intestinal mucosa is evaluated 
by conventional biopsy review, new tools are needed for assess-
ment of mucosal health. The optimal timing of biopsy to eval-
uate healing should be a clinicopathological decision dependent 
on treatment offered and taking into account possible sampling 
errors by following protocols for biopsy sites.
In CD, there may be concurrent upper GI pathologies (eg, 
Helicobacter pylori infection,57 58 lymphocytic gastritis59 and 
eosinophilic oesophagitis/oesophageal eosinophilia60) that 
should be assessed at initial endoscopy if clinical history is 
suggestive, and if present, reassessed post-treatment because 
these may contribute to ongoing symptoms not related to small 
intestinal damage.
Patients included in studies for CD therapy must have had 
an initial robust diagnosis. Occasionally, patients will have been 
diagnosed without histological confirmation.61 These patients 
should not be included in gluten challenge studies but instead 
included in trials of active CD treatment. Patients with a study 
entry biopsy confirming villous atrophy (VA) and a record of 
positive serology and permissive HLA status should be eligible 
for treatment studies in CD.
As per the current European Society for Paediatric Gastroen-
terology Hepatology and Nutrition guidelines,40 we are reluctant 
to suggest timelines for control biopsies for children, although a 
recent paper found that mucosal healing may not be as complete 
as previously assumed.62 For now, follow-up biopsy in children 
should be dictated by clinical needs.
Table 1 summarises changes in mucosal histopathology, 
serology and symptoms in clinical trials with gluten challenge.
Recommendations: Histology is an essential outcome measure 
in any trials of CD treatment (grade B). Histology should be 
performed both before and at the end of the trial when healing 
or histological relapse is the primary outcome measure (grade 
B). In a gluten challenge study, successful treatment may be char-
acterised as no change, or, in a treatment study, as histological 
improvement by a significant increase in the villous height:crypt 
ratio (>0.4 being considered relevant) and/or a ≥30% change in 
IEL densities (grade D). Additionally, histology may be useful 
as a criterion for study inclusion in which participants in gluten 
challenge studies should have a high villous height:crypt depth 
of >2–3 and participants in treatment trials should have a 
decreased villous height:crypt depth ratio of <2–3 (grade D). 
Histological evaluation should follow a priori histology proto-
cols using quantitative measures.
Vote: agree: 7; strongly agree: 12.
serology
Serology is a cornerstone in the diagnostic workup for 
CD.38 39 63 64 IgA auto-antibodies to TG2 and IgG antibodies 
to deamidated gliadin peptides (DGPs) are central diagnostic 
tests for active CD. In IgA-sufficient patients, IgA-anti-TG2 is 
the most predictive and reproducible single test, although IgA 
EMA performs similarly well in some expert laboratories and is 
often used as a confirmatory test. IgG anti-DGP displays similar 
sensitivity as IgA anti-TG2 but has lower specificity. Selection of 
optimal serological tests is mandatory because not all commer-
cial assays perform equally well.65 66 Importantly, calculation of 
results and thus numerical values for the same samples59 also 
may differ and only tests with a multipoint calibration curve give 
values proportional to serum antibody concentration.40 Differ-
ences in assays can make interpretation in and comparisons 
between clinical trials difficult. This difficulty is in part due to 
different epitopes that are detected by different tests, different 
calibration or to antibodies with lower avidity and speci-
ficity.67–69 Thus, an important shortcoming when using serology 
to evaluate the outcome of gluten challenge is the wide range of 
response. When the UK National External Quality Assessment 
consortium tested the same positive samples in 14 commercial 
anti-TG2 assays, large differences in antibody levels were found, 
consistent with substantial variability for antibodies used in the 
diagnosis of CD.65
Overall, a correlation exists between IgA-anti-TG2 antibody 
titres and the severity of mucosal damage by histology, as well as 
the histological outcome on a GFD.70–73 Yet, a recent meta-anal-
ysis found that serum TG2 and EMA often underestimate the 
degree of VA.74 Antibody titres below diagnostic cut-offs, thus, 
do not predict a normal or near-normal (Marsh I) histology. The 
one caveat is that biopsies usually sample a short segment of 
the (descending) duodenum, whereas active CD can affect large 
portions of the small intestine that occasionally extend down 
to the ileum.75 Therefore, a patient may be in clinical and sero-
logical remission with residual inflammation in the proximal 
duodenum but which is quantitatively much less extensive than 
before.74 Thus, in one of the largest studies to date,76 IgA anti-
TG2 failed to detect 44% of persistent VA (Marsh III) in patients 
with CD on a GFD for >1 year.
Normal serology is generally required for entry into a gluten 
challenge study to ensure that participants do not have severe VA 
prior to gluten challenge. Conversely, serology above diagnostic 
cut-offs has not been used as an inclusion criterion for treat-
ment studies in non-responsive CD because many people with 
a normal serology will still have VA and ongoing symptoms.74 
Participants with elevated serologic tests may respond better to 
some therapies. While this remains to be confirmed, stratifica-
tion by CD antibody levels at study entry should be considered.
In clinical trials, serology may be used in assessing change 
during gluten challenge or to monitor longer treatment studies. 
The antibody response to gluten challenge depends on four 
factors: duration of the previous GFD, daily amount of ingested 
gluten,54 duration of gluten intake and individual factors.
Patients with CD may tolerate different levels of gluten expo-
sure. When low (1–3 g/day) or moderate (3–5 g/day) amounts 
of gluten were administered to 25 Finnish patients with CD 
in remission for 12 weeks, only 67% of the patients with CD 
showed signs of mucosal inflammation and 43% developed 
positive IgA-anti-TG2 antibodies.54 However, in a US study of 
20 adult patients with CD in remission challenged with 3 or 
7.5 g gluten/day for 2 weeks, Marsh III histology developed in 
68% of the patients with CD, whereas anti-TG2 and anti-DGP 
antibodies increased in only 25% for anti-TG2% and 30% for 
anti-DGP. Remarkably, positivity for both antibodies increased 
to 55% and 45% 2 weeks after the end of gluten challenge.77 
A recent study from Norway showed even lower proportion of 
patients responding serologically after 2 weeks.78 Therefore, the 
histology at week 2 and serology at week 4 combined showed a 
gluten response in nearly 90%, with no difference between both 
doses.77 Notably, some rare patients who had been on a GFD for 
years may develop a tolerance to gluten ingestion that may last 
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Coeliac disease
for several years.79 Overall, high serologic titres, or significant 
increases in serologic titres, are predictive of VA, but substan-
tial mucosal changes may occur without a significant change in 
serology.
It is important to note that the serological tests were devel-
oped for the diagnosis of CD. Currently, the Food and Drug 
Administration (FDA) have only cleared use of coeliac serol-
ogies as an aid for diagnosis of patients with suspected CD.80 
This restriction limits how serologies can be used in regulatory 
trials, although they are routinely used for monitoring in clinical 
practice. To date, no manufacturer has submitted a claim for use 
of serological tests for disease monitoring and the FDA is only 
able ‘to review submitted claims’.80 Nonetheless, well validated 
IgA anti-TG2 and IgG anti-DGP tests will be important assets to 
clinical studies by helping to monitor CD activity during short 
and especially longer duration gluten challenge trials. Their 
further validation in ongoing trials may lead to FDA approval 
as secondary or combined (with histology or symptoms) primary 
end points in phase II and III clinical studies (table 1).
Recommendations: Although serology is not approved for 
use as a primary pivotal clinical trial outcome by the FDA, IgA 
TG2 and IgG DGP should, at a minimum, be measured at study 
entry and at completion in trials of CD (grade B). For entry 
into a gluten challenge study, participants should have near-
normal titres, whereas for treatment studies, titres may be either 
elevated or normal, with stratification by serologic titre at study 
entry possibly as an a priori analysis (grade B). Choice of assay 
should be made with care and attention be paid to dynamic 
range, especially around or below the cut-off for normal ranges. 
Preferably, an assay with a calibration curve should be applied. 
Although cut-off ranges for diagnosis may not be optimal for 
monitoring response or predicting VA, any significant increase 
during a trial suggests increasing CD activity and may be used as 
a key outcome in some studies.
Vote: agree: 2; strongly agree: 17.
Immunological tools to measure treatment outcomes
Known innate, and particularly adaptive, immune mechanisms in 
CD, are prime candidates to measure treatment outcomes with 
and without gluten challenge. These may be non-invasive blood 
tests, duodenal biopsies with histological assessment by immu-
nocytochemistry, gene expression signatures or in vitro culture.
With in vivo gluten challenge, there is rapid immune activation 
in the duodenum.81–83 One study found that interferon (IFN)-γ 
was increased both at baseline and with gluten challenge and for 
this reason does not appear to be a useful measure of disease 
activity.82 A whole-blood IFN-γ release assay is a much more 
promising measure for identifying immune responsiveness to 
gluten.84 85
Treated patients with CD and healthy individuals show highly 
variable differences in serum cytokines and chemokine levels.86 
Gluten challenge, however, induces a wave of cytokine release.78
In the lamina propria of the duodenal mucosa gluten peptides 
are taken up by dendritic (antigen-presenting) cells with 
surface HLA-DQ2 or DQ8 MHC molecules to stimulate gluten 
peptide reactive CD4+ T cells.87–90 On day 6 of postgluten 
challenge an increase of active disease gluten responsive T cells 
was seen in peripheral blood.91 92 These T cells can be demon-
strated in Enzyme-Linked ImmunoSpot (ELISPOT) assays of 
cytokines when rechallenged with gluten ex vivo. Overall, 
80%–90% of treated patients with CD in remission will show 
a positive response on challenge. T cells can also be demon-
strated by binding to HLA-DQ-gliadin peptide tetramers, a 
construct consisting of multimers of HLA-DQ2 or HLA-DQ8 
molecules bound to a gluten peptide and a reporter molecule 
giving a signal in flow cytometry.93 94 Here, also 80%–90% 
of challenged patients with CD in remission will have a posi-
tive test.95 However, both the ELISPOT and the HLA-DQ2-
gluten tetramer tests are confounded by large interindividual 
differences and small number of studied patients. Recently, 
the HLA-DQ2-gluten tetramer technology has demonstrated 
disease-specific T cells in the peripheral blood even without 
a gluten challenge.96 This, together with the demonstration 
of restricted T-cell receptors,97 may lead to new outcome 
measurements.
Serum IgA anti-TG2 antibody levels as biomarkers of disease 
activity seem to be a useful tool (see the 'Serology' section). 
Peripheral blood B cells may also prove to be a potential source 
of future biomarkers.98 The local mucosal production of anti-
bodies targeting extracellular TG2 in vivo has shown potential in 
diagnosis,51 but was not informative beyond standard histology 
in a clinical drug trial with gluten challenge.99
Recommendations: Although several immunological markers 
are under development as potential outcome measures, they 
have not been validated for therapeutic trials. At this point, they 
should only be used as exploratory outcomes in phase II and III 
clinical trials (grade D).
Vote: agree: 2; strongly agree: 17.
Gluten immunogenic peptides as a compliance measure
Symptom monitoring, serology and histology are at best indirect 
measures of GFD adherence with imperfect overall accuracy.100 
Similarly, diet questionnaires are poor predictors of gluten 
exposure.100
Gluten immunogenic peptides (GIPs), including the 33-mer 
peptide from α2-gliadin, are resistant to GI digestion.101 102 
Because of this resistance, GIP can be detected in faeces or urine 
and thus provides direct evidence and likely quantitation of 
intake.103 A clinical trial examined correlations between faecal 
GIPs and traditional methods to monitoring the GFD.104 The 
majority (85.7%) of children with CD under 3 years of age had 
faeces negative for GIPs. Among those aged ≥13 years, faecal 
positivity for GIPs rose to 39.2%. More males were positive 
for GIPs in faeces compared with females (60% vs 31.5%, 
P=0.034). Serum IgA anti-TG2 was found negative in 40 of the 
56 patients with GIP-positive stools. Today’s data suggest that 
GIP testing may be superior to questionnaires or anti-TG2 anti-
bodies.104 Furthermore, a strong correlation has been demon-
strated between the absence of GIPs in urine and healing of the 
intestinal epithelium.105 The first therapeutic clinical trials using 
the technology are ongoing (NCT02637141, NCT02633020). 
Whereas coeliac trial investigators and sponsors had to previ-
ously guess whether patients were consuming gluten or adhering 
to the GFD, this technology decreases the guesswork with data 
to accurately interpret results and outliers. The assay could 
possibly be developed for quantitative detection of the rate of 
glutamine residue deamidation in trials aiming at interfering 
with transglutaminase activity.106
Recommendations: GIP testing is a promising tool for eval-
uating and selecting patients for clinical trials in CD aimed at 
reducing toxicity related to gluten exposure (grade D). Hence, 
it should be considered in future trials, especially for trials in 
non-responsive CD for therapies that are designed to prevent 
symptoms because of inadvertent gluten exposure (grade D).
Vote: agree: 4; strongly agree: 15.
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Clinical trial end points
The ideal clinical trial end point should be clearly linked to an 
outcome important to patients, reliable, responsive to treat-
ment, clinically or physiologically proximal to the outcome of 
interest and efficient and scalable for use in diverse clinical trial 
settings. Although in some areas biomarkers may be used as 
primary outcomes in clinical trials, these rarely have sufficient 
data for regulatory acceptance.107 In contrast, clinical outcome 
assessments can be more easily linked to patient well-being: clin-
ical outcome assessments are grouped into PROs, clinician-re-
ported outcomes, observer-related outcomes and performance 
outcomes. Clinician-reported outcomes, such as physician global 
assessment, are of limited value as they do not directly assess 
patient status and generally do not correlate well with PROs. 
Observer-related outcomes can be vital in specific populations, 
such as young children, where direct response is not possible. 
Symptom-focused PROs are the main clinical outcome assess-
ment in use in CD and in gastroenterology overall and are the 
focus of this section, although other clinical outcomes will also 
be discussed.
From a clinical/practical perspective, PROs can be helpful to 
monitor patient status and target quality improvement initia-
tives.108 A growing number of digital devices allow patients to 
track and transmit symptom data to their physician; however, 
for these to be useful for practising clinicians, PROs must be easy 
to administer and interpret, as well as to allow feasible clinical 
interventions.108 In research and clinical trials, the key features 
of PROs that should be considered are high responsiveness to 
change and low participant burden.
For patients, the ideal PRO must focus on the symptoms or 
disease attributes most meaningful to them while again mini-
mising time and complexity of use. In CD, this is particularly 
important given the significant impact on emotional, mental 
and social well-being due to the constant vigilance required 
by the GFD. Finally, from a regulatory standpoint, the ability 
to use a PRO in a pivotal clinical trial to support a labelling 
claim depends on whether its characteristics (eg, concept being 
measured, content validity, conceptual framework, intended 
population, format, scoring) are satisfactory and clearly 
documented in a regulatory dossier, which is now available for 
only a few PROs.109
Presently available PROs frequently used in CD or devel-
oped for CD include the Gastrointestinal Symptom Rating Scale 
(GSRS),110 111 the Celiac Symptom Index (CSI),31 the Celiac 
Disease PRO (CeD-PRO),27 the Celiac Disease Symptom Diary 
(CDSD)112 and the Celiac Disease Assessment Questionnaire 
(CDAQ).113 Of these, the GSRS has been used most frequently, 
ranging from natural history to the effects of the GFD to clinical 
trials of novel therapeutics.110 114–116 The GSRS was developed 
originally for peptic disease and irritable bowel syndrome,117 
but because the symptoms of many GI disorders overlap, it has 
proven useful for a variety of GI disorders, including CD.118 
However, it is not optimised for CD and would not be appro-
priate for use in pivotal trials. Conversely, the CSI was developed 
specifically for CD and has been used in many cross-sectional 
and interventional studies.119 120 However, its development was 
completed before the 2009 FDA guidance109 and thus the CSI 
lacks much of the documentation necessary for regulatory clear-
ance. Conversely, both the CDSD and the CeD-PRO were devel-
oped specifically for regulatory approval of CD therapeutics and 
are preferred instruments for this purpose.
The CDAQ was recently developed and assesses a variety of 
domains: symptoms, dietary burden, worry, stigma, and social 
isolation.121 As such, it is a hybrid of the health-related quality 
of life (HRQoL) tools discussed below and a symptom PRO. It 
is unclear if this instrument were developed and documented 
in line with regulatory guidance: in the CDAQ both constipa-
tion and diarrhoea are evaluated in a single combined question 
that may make changes in these important symptoms difficult to 
assess. However, the incorporation of these or similar HRQoL 
domains related to disease burden is critical in ensuring that 
outcomes are relevant and meaningful to patients.
Across these instruments, there is significant overlap, which is 
expected given the limited number of GI symptoms in general 
(table 2): common to all the PROs are diarrhoea, abdominal 
pain, bloating, and nausea. It should be acknowledged that while 
PROs in general may be developed and tested in specific diseases, 
they will not discriminate between diseases and therefore scores 
Table 2 Symptoms assessed across PROs in CD
symptom CDsD112 CD-PrO27 CsI31 CDAQ121 Gsrs117 CD-Gsrs148
Abdominal pain X X X X X X
Diarrhoea X X X X† X X
Bloating X X X X X X
Nausea X X X X X X
Constipation X X† X
Fatigue* X X X X
Headache* X X X
Skin rash X
Flatulence X X X X
Burping X X
Problems thinking* X X
Incomplete emptying X X
Loss of appetite X
Hunger pains X X X
Stomach rumbling X X X X
Reflux X
*Removed from final PRO as per the Food and Drug Administration recommendations.
†Assessed in a single domain.
CD, coeliac disease; CDAQ, Celiac Disease Assessment Questionnaire; CDSD, Celiac Disease Symptom Diary; CSI, Celiac Symptom Index; GSRS, Gastrointestinal Symptom Rating 
Scale; PRO, patient-reported outcome.
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for patients with different GI disorders will overlap.122 There 
is also a poor correlation between symptoms, histology, and 
serology80 123 that is due in part to a different time to response 
after gluten exposure or coexisting symptoms due to irritable 
bowel syndrome or undetected food allergy.124 Thus, it is also 
clear from recent clinical trials that many symptomatic patients 
have no histological or serologic evidence of active CD and 
many patients with significant enteropathy have few or no symp-
toms.78 80 112 116 125 Meanwhile complete recovery of small intes-
tinal lesions is very rare in adult CD patients despite symptom 
disappearance.126
In addition, PRO use in CD can be challenging because of 
symptom heterogeneity (eg, asymptomatic or paucisymptomatic 
patients) and variable extraintestinal manifestations, for which 
no PROs are available. In contrast to disorders such as chronic 
constipation or headache in which one symptom defines the 
condition, symptoms in CD can vary substantially between indi-
viduals and hence careful attention to PRO use is mandatory. 
Moreover, responsiveness to change of non-symptom-based 
dimensions in PROs can vary significantly and must be carefully 
assessed in relation to the intervention under investigation. For 
example, measures of quality of life (QoL) may be less amenable 
to change if the intervention does not reduce dietary burden, 
social isolation and stigma, which are closely linked to managing 
the GFD. Comparing overall PRO mean scores at baseline 
and postintervention may dilute the treatment effect if not all 
domains change or if changes cancel out each other (eg, diar-
rhoea improves but results in constipation by disrupting bowel 
movements). Another option is to compare the means only in 
prespecified domains (eg, include diarrhoea but not constipa-
tion). However, this approach may result in a highly selected 
population that is not representative. A more sophisticated 
approach is to limit primary assessment of the effect of inter-
vention to the symptoms most bothersome to a specific patient 
and then to include all individuals with bothersome symptoms 
in the final PRO assessment. Even with this approach, for 
treatment trials, only patients with symptoms measured by the 
primary PRO outcome can be enrolled. Given the heterogeneity 
of CD, it is likely that sequential trials will need to be performed 
with different outcomes in order to understand the utility of a 
particular therapy. For example, a therapy found to be useful in 
improving GI symptoms in CD could be assessed in a later trial 
assessing itch in patients with dermatitis herpetiformis.
Particularly noteworthy is that while great progress has been 
made in PROs in CD, there is limited experience using the more 
recent PROs in languages other than English and none has 
been validated for use in paediatric populations. Although it is 
expected that the PROs developed for CD in adults will be appli-
cable for paediatric populations, this still requires validation. For 
example, young children and teens may define improved QoL 
differently because of unique challenges in school, social settings 
and peer relationships. Furthermore, improvement in extraint-
estinal symptoms, including behavioural changes, may be more 
relevant among paediatric patients. Development of formats 
suitable for caregivers of children unable to independently 
complete the questionnaires must also be advanced. Develop-
ment of responder definitions and minimal clinically important 
change are additional areas requiring development to realise the 
potential of CD PROs in clinical research.
Given that the relative SD of histology is substantially smaller 
than that of symptoms, for a study where several hundred 
patients are needed to adequately detect differences in symp-
toms, fewer patients may be needed for the histology end point. 
Under such circumstances, researchers may choose to perform 
histology on a random sample of study participants provided 
that they have sufficient study power for the histology end point.
Recommendations: Clinical end points must be included in 
trials of CD and generally PROs should be a primary outcome 
in studies of treatment of active CD, generally late phase II and 
III (grade D). Thus far, there is insufficient evidence to recom-
mend one specific scale, although the CDSD and the CeD-PRO 
appear most likely to meet regulatory requirements (grade D). 
Given the heterogeneity of symptoms in patients with CD, it 
is adequate to limit analyses to certain domains, either in the 
study overall or to allow for participant-specific symptom assess-
ments. However, such decisions should be made at study entry 
and rigorously documented.
Vote: agree: 3; strongly agree: 16.
Health-related quality of life assessment
Clinical trials must also consider the ongoing psychological 
burden of CD to better understand the outcomes. Many studies 
in different settings suggest that CD has a considerable impact 
on HRQoL.12 127 In untreated CD, GI symptoms and extraintes-
tinal issues, such as isolated anaemia, fatigue and malaise, may be 
responsible for reduced HRQoL.128 In general, the treatment of 
CD results in significant improvement in the HRQoL of symp-
tomatic patients.129 Even in patients with silent or asymptom-
atic screening-detected CD, improvement in both symptoms and 
HRQoL has been shown in numerous studies.116 130–132
Impairment in HRQoL may also contribute to and be impacted 
by psychological disorders (eg, anxiety and depression) seen in 
patients with CD.12 133 Whereas anxiety generally improves after 
diagnosis and treatment CD, depression may exist before and 
persist after diagnosis.134 Moreover, anxiety and depression 
alone or through their impact on HRQoL can impair dietary 
compliance.12 135 The interaction between mood disorders, GFD 
adherence and HRQoL is incompletely understood and should 
be addressed in future trials. Additionally, the burden of a GFD 
may lead to ongoing HRQoL impairment despite symptom relief 
and improved physical well-being after dietary intervention.13 19
Because of small numbers of studies and variations in study 
designs, populations and HRQoL measures, we lack a complete 
understanding of degrees and drivers of HRQoL in individuals 
with untreated and treated CD. There are also few studies about 
the effect of CD treatment in the outcome of depression and 
anxiety. Therefore, further studies are required if we wish to 
know more about this specific aspect of CD.
Although HRQoL is generally not accepted by regulatory agen-
cies as a primary outcome in pivotal trials, this is a key outcome 
for both patients and clinicians and may determine whether a 
therapy succeeds or fails. Arguably, a main goal of therapeutics 
in CD, in addition to histological and symptom improvement, 
is to improve HRQoL. Indeed, it is probable that some patients 
in histological and symptomatic remission could have a signifi-
cant HRQoL benefit from pharmacological therapy owing to a 
reduction in burden of the GFD and anxiety regarding poten-
tial exposures. There are several HRQoL scales that have been 
specifically developed for or used in CD (table 3).
Recommendations: HRQoL in CD is complex and multidi-
mensional and may be a more relevant concern to patients than 
specific symptoms. In any trial aiming to improve CD control 
(as opposed to gluten challenge studies that aim to prevent wors-
ening), measurement of HRQoL should be considered a critical 
end point that may help to determine the overall value of a 
therapy or intervention to both patients and payors (grade D).
Vote: agree: 4; strongly agree: 15.
 o
n
 11 Septem
ber 2018 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2017-314853 on 13 February 2018. Downloaded from 
1417ludvigsson JF, et al. Gut 2018;67:1410–1424. doi:10.1136/gutjnl-2017-314853
Coeliac disease
Table 3 Quality of life instruments relevant to coeliac disease
Adult instruments
Instrument Author Participants Instrument description
Generic
  Zung Self Rating Depression Scale149 Ciacci 2003150 581 CD 20-Item self-report, 4-point Likert scale. Assesses four characteristics of depression.
  Gastrointestinal Quality of Life 
Index151
Casellas 2008152 340 CD- 177 untreated vs 
163 on GFD
36-Item self-report, 4-point Likert scale. Assesses five domains: symptoms, physical function, emotional 
function, social function and medical function.
  COPE (brief)153 Smith 2011154 156 CD 28-Item self-report, 4-point Likert scale. Measures 14 coping responses.
Sainsbury 2013155 189 CD
  EuroQol-5D156 Casellas 2008152 340 CD 5-Item self-report, 5-point Likert scale plus a general health rating (scored on a 20 cm visual analogue scale). 
Measures five dimensions: mobility, self-care, daily activities, pain/discomfort and anxiety/depression.Grey 2010157 783 CD
Norström 2011158 1031 CD
Casellas 2015159 366 CD on GFD>1 year
Ramirez-Cervantes 
2015160
80 CD on GFD≥6 months
  Beck Depression Inventory161 Borghini 2016162 210 CD (70 untreated vs 70 
on GFD 6–12 months vs 70 
on GFD>12 months)
21-Item self-report, 4-point Likert scale. Evaluates 21 symptoms of depression, including emotions, behavioural 
changes and somatic symptoms.
Nachman 2009128 132 Newly diagnosed CD
Nachman 2010163 53 Newly diagnosed CD
  Psychological General Well-Being 
Index164
Ford 2012165 288 CD 22-Item self-report, 6-point Likert scale. Includes six dimensions: anxiety, depressed mood, positive well-being, 
self-control, general health and vitality.Smith 2011154 156 CD
Mustalahti 2002131 19 screen-detected CD vs 21 
symptom-detected CD
Mahadev 2016127 211 (71 screen-detected CD 
vs 140 symptom-detected 
CD)
Borghini 2016162 210 CD (70 untreated vs 70 
on GFD 6–12 months vs 70 
on GFD>12 months)
Paavola 2011130 466 CD (96 screen detected 
CD vs 370 symptom-
detected CD vs 110 non-CD 
controls)
Peräaho 2004166 39 CD
Viljamaa 2005167 98 CD (54 screen-detected 
CD vs 44 symptom-detected 
CD)
Ukkola 2011132 698 CD
Smith 2011154 156
Paarlahti 2013168 596 CD
  Hospital Anxiety and Depression 
Scale169
Häuser 2007170 516 CD 14-Item self-report, 4-point Likert scale. Seven items pertain to anxiety and seven to depression.
Häuser 2006171 446 CD
Barratt 2011172 225 CD
Barratt 2011173 225 CD
Ramirez-Cervantes 
2015160
80 CD on GFD≥6 months
  The Short-Form 36-Item QoL 
measure174
Bakker 2013175 57 CD+T1D 36- Item self-report, 3-point, 5-point and 6-point Likert scales as well as binary (yes/no) response items. 
Measures eight domains: physical functioning, role limitations due to physical health, role limitations due to 
emotional problems, energy/fatigue, emotional well-being, social functioning, pain and general health.
Usai 2002176 58 CD
Usai 2007177 129 CD
Barratt 2011172 225 CD
Barratt 2011173 225 CD
Hallert 1998115 89 CD
Viljamaa 2005167 98 CD
Johnston 2004178 14 CD
Häuser 2006170 516 CD
Häuser 2006171 446 CD
Nachman 2009128 132 Newly diagnosed CD
Nachman 2010163 53 Newly diagnosed CD
Hopman 2009179 53 CD
Tontini 2010180 43 CD
Aksan 2015 205 CD
CD-specific scales
Continued
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Adult instruments
Instrument Author Participants Instrument description
  Celiac Disease Questionnaire30 Häuser 2006170 516 CD 28-Item self-report, 7-point Likert scale. Measures four domains: emotional and social problems, disease-
related worries and GI symptoms.Zampieron 2011181 187 CD
Ford 2012165 288 CD
Marchese 2013182 171 CD
Sainsbury 2013155 189 CD
Pouchot 2014183 211 CD
Aksan 2015 205 CD
  Celiac Disease Quality of Life 
Survey29
Mahadev 2016127 211 CD 20-Item self-report, 5-point Likert scale. four subscales: limitations, dysphoria, health concerns and inadequate 
treatment.Zingone 2011184 230 CD
Casellas 2013185 298 CD
Casellas 2015159 366 CD on GFD>1 year
Lee 2016186 2138 CD
Rodriguez-Almagro 
2016187
1230 CD
Russo 2017188 19 CD
Castilhos 2015189 103 CD
Dowd 2017190 220 CD
Fatigue scales
  The Chronic Fatigue Syndrome 
Questionnaire191
Siniscalchi 2005192 130 CD 8–Item self-report for physical fatigue and five items for mental fatigue. The score ranges from 0 to 26.
  The Fatigue Severity Scale193 9-Item self-report (score range 1–7 according to patient’ agreement)
The scores range from 9 to 63.
  Daily Fatigue Impact Scale 
Questionnaire194
Jordà 2010195 51 CD 8-Item self-report questionnaire, five alternative responses per item (from 0=no problem, to 
4=extreme problem).
Eating disorder scales
  Binge Eating Staircases196 Passananti 2013197 100 CD 16-Item self-report. Measures the behavioural aspects of binge eating, as well as feelings and thoughts 
associated with binge eating.
  Eating Attitudes Test 26198 Passananti 2013197 100 CD 26-Item self-report, multiple choice. Assesses diet-related disorders, bulimia and anxiety-related to food.
  Eating Disorder Inventory 2199 Passananti 2013197 100 CD 91-Item self-report (range 0–78); 11 scales, eg, inadequacy, interceptive awareness, fear of maturity, 
asceticism, impulsivity and social insecurity.Wagner 2015200 259 CD adolescents
Karwautz 2008201 283 CD adolescents
  Eating Disorder Examination 
(EDE)202
Wagner 2015200 259 CD adolescents 45–60 min semi-structured interview (28-day recall). Four subscales: restraint, eating concern, shape concern, 
weight concern.Karwautz 2008201 283 CD adolescents
  Eating Disorder Examination 
Questionnaire (EDE-Q)203
Karwautz 2008201 283 CD adolescents 28-Item, self-report. Uses same subscales as the EDE interview.
Sleep disorders scale
   Pittsburgh Sleep Quality Index204 Zingone 2010205 60 CD 19 self-rated items (15 multiple choice and 4 write in)+5 questions rated by a bed partner or roommate (range 
0–57).
Paediatric scales
  TNO-AZL Children’s QOL 
questionnaire (TACQOL) parent206 
and child207 report
Kolsteren 2001208 133 CD children Generic–two forms for children and parents: The TACQOL comprises seven scales (range0–16):
 ► Generic: Dutch Children TNO-AZL QOL Questionnaire 25 items with four.
 ► Domains: emotional, social, familiar, and physical.
van Koppen 2009209 32 CD children
  DUX-25210 van Koppen 2009209 32 CD children (Ages 5–16) 25-item self-report with four domains: physical, emotional, social and home functioning.
  Inventory of Life Quality in Children 
and Adolescents211
Wagner 2008212 365 CD adolescents 9-Item self-rating questionnaire
Nine areas: school, family, social peer contacts, interests and leisure activities, physical health, psychological 
health, overall QoL judgement and disease and therapy-associated burden.
  Berner Subjective Well-being 
Inventory213
Wagner 2008212 365 CD adolescents 39-Item self-report questionnaire, with 4-point and 6-point Likert scale questions.
  PedsQL core: Paediatric Quality of 
Life Measurement Inventory214
Sud 2012215 28 CD+ type 1 diabetes 
children
Four areas: physical functioning (eight items), emotional functioning (five items), social functioning (five items) 
and school functioning (five items).
Biagetti 2015216 76 CD children
Sevinc 2016217 52 CD children
  WHOQOL-BREF218 de Lorenzo 2012219 33 CD child/parent dyads 
vs 62 control child/parent 
dyads
26-Item self-report (parent), 5-point Likert scale. Six domains: loneliness, general health perception, physical 
and psychological functioning, social and environmental.
  Autoquestionnaire de l’Enfant Imagé 
-AUQUEI (child form)220
de Lorenzo 2012219 33 CD child/parent dyads 
vs 62 control child/parent 
dyads
26-Item self-report (child), explores familial and social relationships, physical activity, health, body functions 
and temporary separation from the familial environment.
  EuroQol-5D156 Nordyke 2011221 153 screen-detected CD 
children and 66 known CD 
vs non-CD controls
5-Item self-report, 5-point Likert scale, plus a general health rating (scored on a 20 cm visual analogue scale) 
(child friendly pilot and proxy used).
Nordyke 2013222 207 CD vs non-CD controls
  DISABKIDS Chronic (short version)223 Bystrom 2012224 160 CD child/parent dyads 12-Item self-report Likert scale for ages 8–18 (additional available version for ages 4–7) mental, social and 
physical domains.
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DIsCussIOn
strengths and limitations
In this review, a large number of authors reviewed the literature 
on treatment outcomes in coeliac trials to issue recommenda-
tions for future trials. Our research team was multidisciplinary 
and the treatment outcomes we have evaluated in the paper 
reflect the expert views of the authors.
We performed an extensive literature review of more than 
10 000 papers, and based our deliberations on personal expe-
riences and expertise from our treatment of patients with CD 
with clinical trials and our research in CD. There are already a 
number of guidelines for reporting treatment outcome in CD.136 
Hence, our paper is not meant to give authoritative advice on 
the study design, which is not yet possible because of the devel-
oping nature of the field, but to complement available literature 
with our expertise with a focus on how to measure response to 
non-GFD treatment.
CD is a lifelong disease in which the GFD is the only treat-
ment option. However, we suspect that soon other alternative 
treatments will become commonplace.
Regulatory agencies are responsible for evaluating new therapies 
based on risks and benefits to patients in how they feel, function 
or survive.80 These aims are of intuitive value to patients and clini-
cians and sufficiently broad that they should form the foundation 
of any interventional clinical trial. Despite this, the precedent in 
many fields, including gastroenterology, has been the use of poorly 
validated outcomes of limited applicability to clinical practise. 
Although CD adversely impacts survival6 137 138 and function,139–143 
these outcomes are generally not feasible to assess in clinical trials 
because of low prevalence and long latency. This leaves the options 
of measuring how patients feel—mainly using PROs, histology 
and serology—to assess changes in risk of future adverse events. 
Ideally, a treatment should result in improvement in more than 
one outcome measures (PROs, histology and serology), and that 
is possible using a coprimary end point. However, coprimary 
end points should be used with caution since they decrease study 
power and the number of patients is often limited.
There are currently several well-designed and partially validated 
PROs developed for CD that should be considered standards for 
trials in the future. Assessment of extent (degree) of enteropathy 
(intestinal architecture and IEL assessment) should be consid-
ered as a critical outcome in clinical trials of CD. However, it is 
recognised that technical limitations of duodenal biopsy as a reflec-
tion of overall small intestinal mucosal disease limit the potential 
value of histology as an end point. Development techniques that 
better evaluate enteropathy across the small intestine are applicable 
in clinical practise and relevant to patients.
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Adult instruments
Instrument Author Participants Instrument description
  12-Item Short Form Survey (SF-12)225 Altobelli 2013226 140 CD children 12-Item questionnaire, eight domains: physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional and mental health.
  Impact Scale of Childhood 
Diseases227
Di Filippo 2013228 45 CD children 30-Item self-report, four domains: impact of disease and treatment, impact on child development and 
adjustment, impact on parents and impact on family.
  Kidscreen229 Myleus 2014230 328 CD children 52-Item self-report, measures overall HRQoL along with 10 HRQoL subdomains capturing physical well-being, 
psychological well-being, moods and emotions, self-perception, autonomy, parent relation and home life, 
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  Children’s Depression Inventory231 Simsek 2015135 25 CD children 27-Item, self-report, symptom-oriented scale
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  General Purpose Health-Related 
Quality of Life Questionnaire for 
Children232
Simsek 2015135 25 CD children 40-Item, self-report, four domains: psychological well-being, social relationships, physical function and 
everyday life activities.
  CD-specific (paediatric) scales
  TACQOL-COE Kolsteren 2001208 133 CD children CD-specific instrument (based on TACQOL) TACQOL-COE-DIET:
Five questions to address GFD.
  CDDUX233 Van Koppen 2009209 32 CD children 12-Item questionnaire, three domains: communication, having CD and diet.
Pico 2014234 118 CD child/parent dyads
Torres 2016235 214 CD child/parent dyads 
and 52 CD children
Lins 2015236 33 CD children
Vriezinga 2016237 78 CD children
Meyer 2016238 34 CD child/parent dyads
  Celiac Disease Paediatric Quality of 
Life Scale239
Jordan 2013239 
(validation study)
181 CD children 13-Item (ages 8–12) and 17-item (ages 13–18) scale. Home, school, social and self-esteem (also diet and 
future in 13–18 tool).
Ages 8–18 only.
CDDUX, celiac disease DUX.
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